Tuesday, October 6, 2015

These Russian Scientists Are On A Quest To Extend Human Life

Alexander Zhavoronkov—age 37—is convinced he'll personally surpass the current record for longest life.


It's questionable if extending life in itself is a particularly commendable or noble goal of scientific research. There are already a lot of people in the world, and many of them are already living significantly longer than people used to. Allowing a few people to live a few extra years doesn't seem urgent in the way other scientific goals certainly are.

The quest to extend life, though, has lately become an obsession among a certain Silicon Valley crowd—a moonshot sort of thing. Heavyweights like Peter Thiel, Larry Ellison, Peter Diamandis, and Craig Venter are putting significant energy and money towards the goal.

"There's a convergence of IT and biomedicine," says Alexander Zhavoronkov, who's part of the extending life scene. "There are more and more people from the IT industry entering the biomedical field. Many people in aging research come from IT."



Zhavoronkov, ex-director of semiconductor company ATI Technologies, has organized several major conferences, including one recently in Basel, Switzerland, where Thiel gave the keynote. Zhavoronkov also has his own company, In Silico Medicine, which he runs out of an office on the Johns Hopkins campus in Baltimore, and serves as an adjunct professor at Moscow Institute of Physics and Technology and director of the Biogerontology Research Foundation.

In other words, Zhavoronkov, who is 37, is a busy man. Speaking to him recently, I got the sense of a flurry or initiatives. The Russian sees extending life as an absolutely worthwhile goal. He views aging not as inevitable, but a failure of science to give people a few more years. "Large pharma doesn't view aging as a disease yet," he complains. Zhavoronkov also wants to bring credibility to a field where diet and exercise companies make scientific-sounding claims that often aren't true.
Alexander Zhavoronkov and his collaborator Alexey Moskalev recently launched the Geroprotectors.org database, an attempt to collect all the legitimate science of anti-aging in one place (see their report here).

The more than 230 chemicals listed have all shown potential in experiments either to slow down aging or in actually repairing age-related damage (bringing "the old state closer to the young state"). Most of the experiments were on simpler animals like flies, worms and mice. Zhavoronkov hopes the entries will be jumping-off points for other scientists to do biostatistical analysis and modeling on human extrapolations.

"Our idea is to put it out in the open so that people can design algorithms to connect it to clinical trials and other data and make predictions on their attractiveness [of geroprotectors] to humans," Zhavoronkov says.

In Silico Medicine is working on several of the candidates in the database, including N-acetylcysteine and metformin. Zhavoronkov is also doing a fair amount of self-testing. And he's confident that what he's taking him will allow him to live longer than the oldest woman ever (Jeanne Calment) who died at the age of 122. "I take 200 compounds to see the effects on the blood. I'm think I'm going to beat Jeanne Calment for sure," he says.

Geroprotector science could have positive impacts for work on cancer and Alzheimer's, Zhavoronkov says. But, to me at least, it also feels a tad self-indulgent. With so many other needs in the world, adding a few extra years to a few Silicon Valley guys doesn't seem like a pressing problem. But then that's going to stop people from trying.

Tuesday, September 22, 2015

New method for testing iPSC differentiation potential could lead to safer and more potent treatments

The discovery of human induced pluripotent stem cells (iPSCs) in 2006 completely revolutionized the field of stem cell biology. iPSC lines have become powerful tools that can be used to study human embryonic development, as model systems for human diseases. They are also helpful as a renewable source for regenerative medicine, where these cells are expected to play a key role in the development of many regenerative medicine therapies.

During recent collaboration, two companies, Atlas Regeneration and Insilico Medicine, demonstrated the close resemblance of iPSCs with ESCs at the pathway level, and provided examples of how pathway activity analysis can be applied to identify iPSC line abnormalities or to predict in vitro differentiation potential. The results indicate that pathway activation profiling is a promising strategy for evaluating the safety and potency of iPSC lines in translational medicine applications allowing scientists to test differentiation abilities of many iPSC lines in silico while saving valuable time for patients waiting for treatment.

Evgeny Makarev, Ph.D, COO of Atlas Regeneration, Inc., the leader of the study, said, "Regeneration Intelligence is unique among pathway analysis platforms. Using our algorithm along with proprietary pathway database, we established for the first time pathway activation profiles of iPS. We reused data from publically available gene expression data sets and evaluated signaling and metabolic pathway activation profiles for 20 human embryonic stem cell (ESC) lines, 12 human iPSC lines. Consequently, we identified PAS quality score lines as a novel prognostic biomarker that can identify impaired iPSC lines."

Anthony Atala, MD, CEO of Atlas Regeneration said, "Our Regeneration Intelligence platform has been used in many iPSC lines and is helping stem cells biologist to improve and speed up decision-making. Unfortunately, the entire process of verification and validation of differentiation abilities using in vitro differentiation assays typically takes 12 weeks and time is critical for definitive treatment, especially in urgent cases. With the help of Regeneration Intelligence, we may be able to significantly reduce the time and cost of the process."

About Atlas Regeneration, Inc. 
 
Atlas Regeneration is a Winston Salem, N.C.-based company utilizing advances in multiomics and big data analysis for drug discovery and regeneration targeting aging and age-related diseases. The company utilizes the Regeneration Intelligence™ and PharmAtlas™ packages for pathway analysis in aging and stem cells research, pursues internal drug discovery programs, and provides services to pharmaceutical companies. For more info please visit http://atlasregeneration.com

Tuesday, September 15, 2015

The Economist's annual Innovation Awards & Summit event in Hong Kong

Dmitry Kaminskiy, senior partner at Deep Knowledge Ventures is making headlines in Asia. In October he will be giving a talk on exponential technologies (‪#‎transhumanism‬) and artificial intelligence together with the chief scientist at NASA, vice-chairman of General Electric and many others at The Economist's annual Innovation Awards & Summit event in Hong Kong.
This event attracts some of the most interesting people in Asia and is an excellent networking platform for C-level executives.
Come to Hong Kong on the 14th of October and hear Dmitry Kaminskiy's talk.